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To be eligible for inclusion in the Emerging Risk Factors Collaboration (ERFC), prospective studies (reported variously as 
observational cohort studies, trials, or analyses of nested case-control or case-cohort subsets) had: (1) data available from baseline 
measurements of at least one of the relevant markers assessed; (2) at least 1 year of follow-up; (3) participants not selected on the 
basis of having previous cardiovascular diseases; and (4) information on cause-specific mortality and/or major cardiovascular 
morbidity collected during follow-up. Studies were prioritized for inclusion if they were known to have recorded at least 20 000 
person years at risk. Most eligible studies were identified in previously published meta-analyses, with additional studies identified 
through updated computer-assisted literature searches of databases, scanning of reference lists, hand-searching of relevant journals 
and correspondence with authors of relevant reports. Further details of the ERFC (including search strategies, contributing studies, 
data provision and management, and other characteristics) have been reported previously (Eur J Epidemiol. 2007;22:839-869).  
* None of the participants in GLOSTRUP and USPHS2 had a history of diabetes at baseline, and fasting glucose information was not 
provided. All of the participants with relevant information in NORTH KARELIA and PREVEND had a history of diabetes, and 
fasting glucose information was not provided. Data from EAS, LASA and WHI-HaBPS had not been fully harmonised by the ERFC 




















121 studies included in the 
 Emerging Risk Factors Collaboration  
by May 2010 
12 studies did not have information 
at baseline examination on either 
diabetes status or fasting blood 
glucose concentration 
97 studies (involving 592 830 
participants) were included in 
analyses of diabetes 
54 studies (involving 288 483 
participants) were included in 
analyses of fasting blood glucose 
102 studies (involving 698 782 
participants) were included in the current 
analyses 
7 studies provided relevant 
information but were not included in 
the current analyses* 
  3




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































A    Age-adjusted prevalence of diabetes, by sex 
B    Age- and sex-adjusted prevalence of diabetes, by study-specific definition of history of diabetes 
C     Age- and sex-adjusted prevalence of diabetes, by geographical region  
Based on self-report only Based on self-report 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































People were classified as having diabetes based on self-report or fasting glucose ≥7 mmol/L. Prevalence was adjusted 






































































































































































































































































































































































































































































































































































eFigure 4 Cross-sectional correlates of fasting glucose concentration in people without known 
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0.19 (0.18 to 0.21) 0.20 (0.17 to 0.24) 0.24 (0.22 to 0.27)
0.17 (0.15 to 0.18) 0.13 (0.11 to 0.14) -0.09 (-0.12 to -0.07)






























































For all correlates except age, response means are adjusted to age 60. For continuous risk markers, values 
presented are the Pearson’s correlation coefficient (95% CI) for the association between the risk marker and 




eFigure 5 Age- and sex-adjusted regression dilution ratios for fasting glucose measurements in people without 
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Analyses were based on 201 814 repeat (re-survey) measurements from 65 223 participants with information on fasting 
glucose concentration from more than one survey. For each re-survey, studies with fewer than 50 participants were excluded. 
In people with known diabetes at baseline, the pooled RDR was 0.49 (0.44 - 0.54). 
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eFigure 6        Hazard ratios for coronary heart disease and ischaemic stroke in people with diabetes at baseline compared with people without diabetes, by additional   
                        characteristics  
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People were classified as having diabetes based on self-report or fasting glucose ≥7 mmol/L. Regression analyses were stratified, where appropriate, by sex and trial group, and 
adjusted for age, smoking status, BMI and systolic blood pressure.  Studies with fewer than 11 cases of an outcome were excluded from the analysis of that outcome. P-values for 
interaction were calculated from analyses using continuous variables where appropriate. Sizes of data markers are proportional to the inverse of the variance of the hazard ratios.    
Non-HDL-C: Bottom, middle and top third defined as <3.83, 3.83 to <4.83, and ≥4.83 mmol/L with mean values of 3.17, 4.33, and 5.72 mmol/L respectively. HDL-C: Bottom, middle 
and top third defined as <1.14, 1.15 to <1.45, and ≥1.45 mmol/L with mean values of 0.96, 1.29, and 1.79 mmol/L respectively.  Log-triglycerides: bottom, middle and top third 
defined as <0.07, 0.08 to <0.52, and ≥0.52 with mean values of -0.24, 0.29, and 0.91 respectively. There was no significant association between overall or sex-specific prevalence of 









eFigure 7 Hazard ratios for coronary heart disease and ischaemic stroke by baseline fasting glucose concentration between 3.9 and 5.6 mmol/L, in 
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Analyses were based on 179 659 participants (9479 cases) for CHD and 124 414 participants (967 cases) for ischaemic stroke. Participants were classified into tenths of 
fasting glucose for CHD and fifths for ischaemic stroke. Hazard ratios are plotted against the mean fasting glucose in each group. Reference groups are: the 8th quantile 
for CHD and the 4th quantile for stroke (ie, the quantile that contains the overall mean). Regression analyses were stratified, where appropriate, by sex and trial group, 
and adjusted for age, smoking status, BMI and systolic blood pressure. Studies with fewer than 11 cases of an outcome (with fasting glucose between 3.9 and 5.6 
mmol/L) were excluded from analysis of that outcome. Sizes of data markers are proportional to the inverse of the variance of the hazard ratios. 
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eFigure 8           Hazard ratios for coronary heart disease in people with impaired fasting glucose, by individual-        
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Impaired fasting glucose was defined as those without known diabetes at baseline and fasting glucose values between 
5.6 and 6.99 mmol/L (according to ADA criteria). HRs were calculated in reference to people with fasting glucose 
values below 5.6mmol/L. Regression analyses were stratified, where appropriate, by sex and trial group, and adjusted 
for age, smoking status, BMI and systolic blood pressure.  Studies with fewer than 11 coronary heart disease cases were 
excluded from analysis. P-values for interaction were calculated from analyses using continuous variables where 
appropriate. Sizes of data markers are proportional to the inverse of the variance of the hazard ratios. Numbers of 






eFigure 9 Hazard ratios for vascular outcomes in people with diabetes at baseline compared with 
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Analyses were based on up to 524 422 participants from up to 82 studies. People were classified as having 
diabetes based on self-report or fasting glucose ≥7 mmol/L. Regression analyses were stratified, where 
appropriate, by sex and trial group, and adjusted for age, smoking status, BMI and systolic blood pressure.  
Studies with fewer than 11 cases of an outcome were excluded from the analysis of that outcome. Sizes of data 
markers are proportional to the inverse of the variance of the hazard ratios.  



































Mean fasting glucose concentration (mmol/L)  Mean fasting glucose concentration (mmol/L)  
5 7 9 11
A     In all participants   B   In participants with baseline fasting glucose concentration 
between 3.9 and 5.6 mmol/L and no known history of   
diabetes at baseline
No known history of diabetes at baseline, HRs estimated using a 1-stage stratified Cox model   
Known history of diabetes at baseline, HRs estimated using a 1-stage stratified Cox model   




























Regression analyses were stratified, where appropriate, by sex and trial group, and adjusted for age, smoking status, BMI and systolic blood pressure. Studies with fewer 
than 11 CHD cases and all case-control studies were excluded. Sizes of data markers are proportional to the inverse of the variance of the hazard ratios.  Analyses in (a) 
were based on 276 964 participants (14 458 cases).  Participants with fasting glucose values in the top and bottom 0.2% were excluded. Participants without known 
diabetes at baseline are classified into groups of fasting glucose: <4, 4-4.5, 4.5-5, 5-5.5, 5.5-6, 6-6.5, 6.5-7, 7-7.5 and >7.5 mmol/L. The reference group is defined as 
those without known diabetes with glucose values between 5 – 5.5 mmol/L. Analyses in (b) were based on 178 164 participants (9263 cases). Participants are classified 
into tenths of fasting glucose. The reference group is the 7th quantile.  
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eFigure 11 (a) Study-specific hazard ratios for coronary heart disease in people with diabetes at baseline compared with 
people without diabetes 
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Regression analyses were stratified, where appropriate, by sex and trial group, and adjusted for age, smoking status, BMI and systolic 
blood pressure. Studies are ordered (top to bottom) by increasing number of CHD cases. Studies with fewer than 11 CHD cases were 
excluded from analysis. Sizes of data markers are proportional to the inverse of the variance of the hazard ratios.   
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eFigure 11 (b) Study-specific hazard ratios for ischaemic stroke in people with diabetes at baseline compared 
with people without diabetes 
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Regression analyses were stratified, where appropriate, by sex and trial group, and adjusted for age, smoking status, BMI and 
systolic blood pressure. Studies are ordered (top to bottom) by increasing number of ischaemic stroke cases. Studies with fewer 
than 11 ischaemic stroke cases were excluded from analysis. Sizes of data markers are proportional to the inverse of the 
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Analyses were based on 279 290 participants (14 814 cases) for CHD and 175 542 participants (1754 cases) for ischaemic stroke. Participants are classified into groups of 
fasting glucose (coronary heart disease: <4, 4-4.5, 4.5-5, 5-5.5, 5.5-6, 6-6.5, 6.5-7, 7-7.5 and >7.5 mmol/L; ischaemic stroke: <4.5, 4.5-5, 5-5.5, 5.5-6, 6-7, and >7 mmol/L). 
Hazard ratios are plotted against the mean fasting glucose in each group. The reference group for both outcomes is 5-5.5 mmol/L. Regression analyses were stratified, where 
appropriate, by sex and trial group, and adjusted for age, smoking status, BMI and systolic blood pressure. Studies with fewer than 11 cases of an outcome were excluded 
from analysis of that outcome. Sizes of data markers are proportional to the inverse of the variance of the hazard ratios. 
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Analyses were based on 279 290 participants (14 814 cases) for CHD and 175 542 participants (1754 cases) for ischaemic stroke. People were classified as having diabetes based on self-
report or fasting glucose ≥7 mmol/L. Participants without known diabetes at baseline are classified into groups of fasting glucose   (coronary heart disease: <4, 4-4.5, 4.5-5, 5-5.5, 5.5-6, 6-
6.5, 6.5-7, 7-7.5, 7.5-8, 8-8.5, 8.5-9 and >9 mmol/L; ischaemic stroke: <4.5, 4.5-5, 5-5.5, 5.5-6, 6-6.5, 6.5-7, 7-7.5, 7.5-8, 8-8.5, 8.5-9 and >9 mmol/L). Hazard ratios are plotted against 
the mean fasting glucose in each group. The reference group for both outcomes is 5-5.5 mmol/L. Regression analyses were stratified, where appropriate, by sex and trial group, and 
adjusted for age, smoking status, BMI and systolic blood pressure. Studies with fewer than 11 cases of an outcome were excluded from analysis of that outcome. Sizes of data markers are 
proportional to the inverse of the variance of the hazard ratios. 
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eFigure 14 Hazard ratios for coronary heart disease and vascular death in people with diabetes compared with 
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Analyses were based on 524 422 participants (24 898 cases) for CHD and 501 166 participants (23 706 cases) for vascular 
deaths. HRs were estimated using a two-stage approach where study-specific HRs were calculated then pooled across 
studies by random-effects meta-analyses. In the first stage, regression analyses were stratified, where appropriate, by sex 
and trial group, and adjusted for age, smoking status, BMI and systolic blood pressure. In the baseline analyses (indicated 
by red markers) diabetes status was defined only according to the baseline measurement. In the other analyses, diabetes 
status was modelled as a time dependent continuous variable to represent the probability of having diabetes (range between 
0 and 1). Multiple records were used for each participant when available. Up to 428 241 repeat measurements from 179 054 
participants contributed to the analyses. Diabetes status was assessed at baseline and reassessed at each re-survey. People 
were classified as having diabetes based on self-report or fasting glucose ≥7 mmol/L. Participants classified as having 
diabetes kept diabetes status of 1 until time of event. For participants with no known diabetes, the probability of having 
diabetes was calculated according to the incident rates of diabetes (% per year) based on the cumulative exponential 
distribution. Case-control and studies with fewer than 11 cases of an outcome were excluded from analysis of that outcome. 
Sizes of data markers are proportional to the inverse of the variance of the hazard ratios. 
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eTable 1.  Characteristics of the 102 individual studies included in analyses. 
 
Study 
abbreviation Location Population source Sampling method 
No. of 
participants 




Number (%) with 
diabetes at baseline 
Mean (SD) fasting glucose 
(mmol/L) at baseline 
Cohort studies                 
ARIC USA Households Random 14590 54 (6) 6297 (43) 1589 (11) 6.0 (2.1) 
ATENA Italy Volunteers Random 4752 50 (7) 0 (0) 118 (2) - 
ATTICA Greece General population Random 1601 51 (11) 822 (51) 147 (9) 5.3 (1.5) 
BHS Australia Electoral rolls Complete 6221 45 (16) 2940 (47) 122 (2) 5.1 (1.1) 
BRHS UK GP/Health service lists Random 6810 50 (6) 6810 (100) 77 (1) - 
BRUN Italy Population register Random 817 58 (11) 398 (49) 44 (5) 5.5 (1.0) 
BUPA UK GP/Health service lists Complete 20884 47 (8) 20884 (100) 159 (1) 5.4 (1.1) 
BWHHS UK General population Random 3030 68 (5) 0 (0) 245 (8) 6.0 (1.4) 
CAPS UK Electoral rolls Random 2161 52 (5) 2161 (100) 30 (1) 6.3 (2.1) 
CASTEL Italy Screening Complete 2534 73 (5) 963 (38) 484 (19) 6.1 (1.7) 
CHARL USA Households Random 1945 50 (11) 866 (45) 83 (4) - 
CHS1 USA Medicare lists Random 3872 72 (5) 1483 (38) 495 (13) 6.0 (1.8) 
CHS2 USA Medicare lists Random 473 72 (5) 178 (38) 104 (22) 6.5 (2.9) 
COPEN Denmark General population Random 8414 58 (15) 3587 (43) 247 (3) - 
DISCO Italy NR NR 1932 50 (11) 846 (44) 79 (4) - 
DRECE Spain General population Random 2860 41 (11) 1384 (48) 192 (7) 5.3 (1.4) 
DUBBO Australia Electoral rolls Complete 2061 68 (7) 866 (42) 139 (7) 5.1 (1.1) 
EMOFRI Italy General population Random 360 55 (6) 176 (49) 24 (7) 5.4 (1.7) 
EPESEBOS USA General population Complete 1033 72 (5) 353 (34) 131 (13) - 
EPESEIOW USA General population Complete 1588 73 (5) 511 (32) 115 (7) - 
EPESENCA USA General population Random 1348 72 (5) 448 (33) 177 (13) - 
EPESENHA USA General population Random 814 73 (6) 302 (37) 92 (11) - 
ESTHER Germany GP listings Complete 8042 62 (7) 3394 (42) 1055 (13) 5.4 (1.6) 
FINE_FIN Finland NR NR 279 77 (5) 279 (100) 42 (15) 6.1 (2.0) 
FINE_IT Italy Survivors of an existing cohort Complete 475 73 (5) 475 (100) 41 (9) - 
FINRISK92 Finland General population Random 5263 46 (10) 2438 (46) 96 (2) - 
FINRISK97 Finland General population Random 6328 51 (11) 3138 (50) 213 (3) - 
FRAMOFF USA Offspring or spouse to Framingham heart study participants Complete 2854 54 (10) 1269 (44) 
291 (10) - 
GOH Israel General population Random 2772 44 (9) 1380 (50) 255 (9) 8.8 (3.4) 
GOTO13 Sweden General population Complete 766 54 (0) 766 (100) 8 (1) - 
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Study 
abbreviation Location Population source Sampling method 
No. of 
participants 




Number (%) with 
diabetes at baseline 
Mean (SD) fasting glucose 
(mmol/L) at baseline 
GOTO33 Sweden General population Complete 733 51 (0) 733 (100) 54 (7) 5.1 (1.9) 
GOTO43 Sweden General population Complete 773 50 (0) 773 (100) 26 (3) 4.7 (1.3) 
GOTOW Sweden General population Random 1455 47 (7) 0 (0) 27 (2) 4.2 (1.1) 
GREPCO Italy NR NR 815 44 (8) 0 (0) 17 (2) - 
GRIPS Germany Occupational Complete 5786 48 (5) 5786 (100) 124 (2) - 
HBS Finland Occupational Complete 1142 60 (4) 1142 (100) 19 (2) 4.9 (1.0) 
HELSINAG Finland Population register Random 527 79 (4) 131 (25) 0 (0) 5.6 (1.9) 
HISAYAMA Japan General population Complete 2576 59 (12) 1087 (42) 295 (11) 5.8 (1.3) 
HONOL USA GP/Health service lists Complete 2571 78 (4) 2571 (100) 651 (25) - 
HOORN Netherlands General population Random 2230 61 (7) 983 (44) 207 (9) 5.7 (1.5) 
IKNS Japan General population Complete 8043 58 (10) 3300 (41) 1305 (16) 6.0 (1.3) 
ISRAEL Israel Occupational Occupational 7838 49 (7) 7838 (100) 384 (5) - 
KIHD Finland General population Random 2068 53 (5) 2068 (100) 91 (4) 4.7 (1.0) 
MALMO Sweden Screening Random 32495 46 (7) 21923 (67) 630 (2) 5.0 (1.0) 
MATISS83 Italy Electoral rolls Random 2557 51 (10) 1197 (47) 168 (7) 5.3 (1.3) 
MATISS87 Italy Electoral rolls Random 2113 52 (9) 933 (44) 101 (5) 5.3 (1.2) 
MATISS93 Italy Electoral rolls Random 1211 49 (9) 588 (49) 66 (5) 5.0 (1.4) 
MCVDRFP Netherlands General population Random 23111 42 (10) 10704 (46) 231 (1) - 
MESA USA General population Random 6760 62 (10) 3186 (47) 844 (12) 5.4 (1.7) 
MICOL Italy Electoral rolls NR 23196 51 (10) 12810 (55) 1149 (5) - 
MOGERAUG1 Germany General population Random 874 54 (6) 874 (100) 37 (4) - 
MOGERAUG2 Germany General population Random 4025 53 (12) 1974 (49) 200 (5) - 
MOGERAUG3 Germany General population Random 3398 55 (11) 1676 (49) 183 (5) - 
MONFRI86 Italy NR NR 1138 49 (9) 556 (49) 11 (1) - 
MONFRI89 Italy NR NR 1105 48 (8) 545 (49) 14 (1) - 
MONFRI94 Italy Electoral rolls Random 1296 49 (8) 632 (49) 96 (7) 5.7 (1.4) 
MORGEN Netherlands General population Random 17739 46 (9) 8063 (45) 226 (1) - 
MOSWEGOT Sweden General population Random 4157 47 (11) 1972 (47) 99 (2) - 
MRCOLD UK GP/Health service lists Random 10521 80 (4) 3937 (37) 271 (3) - 
NCS1 Norway General population Complete 24238 42 (4) 11943 (49) 189 (1) 5.7 (1.1) 
NCS2 Norway General population Complete 13106 42 (4) 6684 (51) 76 (1) 5.7 (0.8) 
NCS3 Norway General population Complete 10179 42 (4) 5283 (52) 47 (0) 5.6 (0.7) 
NFR Italy NR NR 3133 55 (5) 3133 (100) 202 (6) - 
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Study 
abbreviation Location Population source Sampling method 
No. of 
participants 




Number (%) with 
diabetes at baseline 
Mean (SD) fasting glucose 
(mmol/L) at baseline 
NHANESI USA General population Cluster 11621 49 (15) 4617 (40) 631 (5) - 
NHANESIII USA General population Cluster 12566 54 (16) 5801 (46) 1226 (10) 5.8 (1.9) 
NPHSII UK GP/Health service lists Complete 2968 57 (3) 2968 (100) 74 (2) - 
NSHS Canada General population Random 1944 54 (16) 932 (48) 108 (6) - 
OSAKA Japan General population or occupational Complete 12307 52 (10) 8335 (68) 1231 (10) 5.7 (1.2) 
OSLO Norway General population Complete & random 17392 44 (6) 17392 (100) 221 (1) 5.8 (1.0) 
PARIS1 France Occupational Complete 7079 47 (2) 7079 (100) 385 (5) 5.7 (0.9) 
PRHHP Caribbean General population Complete 6350 54 (6) 6350 (100) 644 (10) 5.4 (1.7) 
PRIME France/NI General population Quota 9582 55 (3) 9582 (100) 385 (4) - 
PROCAM Germany Occupational Complete 20218 44 (10) 14648 (72) 414 (2) - 
QUEBEC Canada General population Random 1307 57 (7) 1307 (100) 90 (7) - 
RANCHO USA Households Complete 1806 68 (11) 744 (41) 133 (7) 5.5 (1.1) 
REYK Iceland General population Complete 16840 52 (9) 8060 (48) 322 (2) 4.5 (0.8) 
ROTT Netherlands General population Complete 4823 68 (8) 1824 (38) 432 (9) 8.7 (4.5) 
SHHEC UK GP/Health service lists Random 10966 49 (7) 5398 (49) 143 (1) - 
SHS USA General population Complete 4131 56 (8) 1614 (39) 2032 (49) 8.3 (4.2) 
SPEED UK GP/Health service lists Complete 2126 55 (4) 2126 (100) 41 (2) - 
TARFS Turkey Households Random 3535 43 (13) 1760 (50) 95 (3) 4.9 (1.2) 
TROMSØ Norway Households Complete 22568 44 (15) 10597 (47) 380 (2) - 
ULSAM Sweden General population Complete 2280 50 (1) 2280 (100) 122 (5) 5.0 (0.9) 
VHMPP Austria Health check-up Complete 66395 49 (13) 32195 (48) 0 (0) 5.0 (1.5) 
VITA Italy Census lists Random 9031 51 (8) 4055 (45) 0 (0) 4.6 (1.3) 
WHITEI UK Occupational Complete 4013 76 (5) 4013 (100) 191 (5) - 
WHITEII UK Occupational Complete 10191 45 (6) 6802 (67) 92 (1) 6.2 (-) 
WHS USA Occupational Complete 28022 55 (7) 0 (0) 770 (3) - 
ZARAGOZA Spain GP/Health service lists Complete 3662 58 (12) 1528 (42) 465 (13) 5.9 (1.6) 
ZUTE Netherlands General population Random 390 76 (4) 390 (100) 30 (8) - 
Case-control studies               
USPHS USA Occupational Complete 934 60 (9) 934 (100) 56 (6) - 
EPICNOR UK GP/Health service lists Complete 1422 66 (8) 966 (68) 46 (3) - 
FIA Sweden General population Random 2624 54 (7) 2116 (81) 106 (4) 5.5 (1.1) 
FLETCHER New Zealand Occupational, electoral rolls Complete & random 477 57 (12) 405 (85) 27 (6) - 
HPFS USA Occupational Random 736 65 (8) 736 (100) 47 (6) - 
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Study 
abbreviation Location Population source Sampling method 
No. of 
participants 




Number (%) with 
diabetes at baseline 
Mean (SD) fasting glucose 
(mmol/L) at baseline 
NHS USA Occupational Random 717 60 (6) 0 (0) 77 (11) - 
Clinical trials                 
AFTCAPS USA Screening Complete 6577 58 (7) 5587 (85) 127 (2) - 
ALLHAT USA/Canada/Puerto Rico/US Virgin Islands General population NR 28146 66 (8) 13806 (49) 
12049 (43) 7.0 (3.3) 
LEADER UK GP listings Complete 941 68 (9) 941 (100) 152 (16) - 
MRFIT USA Screening Complete 12840 47 (6) 12840 (100) 425 (3) 5.5 (0.9) 
PROSPER Scotland/Ireland/ Netherlands Screening Complete 3253 75 (3) 1350 (42) 
477 (15) 5.5 (1.5) 
WOSCOPS UK Screening Complete 6214 55 (6) 6214 (100) 115 (2) 4.8 (0.7) 
Studies with information on history of diabetes at baseline*              
TOTAL (97 studies)   592830 52 (13) 332664 (56) 38851 (7) 5.5 (2.0) 
         
Studies with information on fasting glucose concentration             
TOTAL (54 studies)   288483 53 (12) 172425 (60) 22434 (8) 5.4 (1.8) 
         
All studies                  
TOTAL (102 studies)   698782 52 (13) 398731 (57) 39295 (6) 5.4 (1.8) 
 
*2 studies provided data on previous history of diabetes but were not included in the analyses of diabetes because none of the participants (MRFIT) and all of the participants 
with history of diabetes information (HBS) had diabetes.  3 studies (HELSINAG, VITA and VHMPP) did not provide data on previous history of diabetes.  









eTable 2 Definitions of outcomes assessed in the current report 
 
 
Outcome ICD version 
ICD-9 ICD-10 
Myocardial infarction 410, 412 I21, I22 
Coronary heart disease 410-414 I20–I25 
Ischaemic stroke 433, 434 I63 
Haemorrhagic stroke 431 I61 
Unclassified stroke* 436 I64 
Other cerebrovascular disease 430, 432, 435, 437, 438 F01, I60, I62, I65-I69 
Other cardiovascular outcomes 093, 391, 393-405, 415-417, 420-
429, 440-444, 446-453, 458, 459, 
745-747, 798 
G45, I01, I05-I15, I20, I26-I28, I30-
I52, I70-I82, I87,I95, I97-I99, Q20-
Q28, R96   
 
Corresponding ICD-6, 7 or 8 codes were used for studies that recorded outcomes using earlier ICD versions.  
*Unclassified stroke was defined by the ICD codes stated, or as strokes not specified as ischaemic or haemorrhagic by 




eTable 3 Baseline characteristics of participants with information on self-reported diabetes 
status (with or without supplementary information on fasting glucose) 
 
 
Overall summary statistics 
No of studies No of participants Mean (SD) or % 
Diabetes status  97 592 830  
    Definite 97 38 851 7% 
    Other 97 553 979 93% 
    
Non-lipid markers    
Age at survey (yrs) 97 592 830 52 (13) 
Fasting glucose (mmol/L) 46 182 704 5.6 (1.8) 
BMI (kg/m2) 93 564 889 26 (4) 
Waist-to-hip ratio 37 137 552 0.89 (0.08) 
Waist (cm) 39 138 225 90 (12) 
SBP (mmHg) 92 563 287 136 (19) 
DBP (mmHg) 92 564 874 82 (11) 
    
Lipid markers    
Total cholesterol (mmol/L) 91 549 935 5.80 (1.10) 
Non-HDL-C (mmol/L) 78 359 519 4.48 (1.12) 
HDL-C (mmol/L) 78 359 844 1.34 (0.38) 
Log triglycerides 77 440 829 0.32 (0.52) 
Apo B (g/L) 27 110 309 1.08 (0.28) 
Apo AI (g/L) 26 112 931 1.46 (0.27) 
    
Inflammatory markers    
Log-CRP  40 116 926 0.66 (1.11) 
Fibrinogen (g/L) 40 178 774 3.23 (0.71) 
    
Categorical variables    
Sex 97 592 830  
    Male 91 332 664 56% 
    Female 69 260 166 44% 
    
Race 74 417 422  
    Non-white 26 61 510 15% 
    White 68 355 912 85% 
    
Geographical region 97 592 830  
    North America 23 1362 88 23% 
    Europe 65 407 933 69% 
    Australia 2 8248 1% 
    New Zealand 1 477 <0.5% 
    Israel 2 10 610 2% 
    Japan 3 22 926 4% 
    Caribbean 1 6348 1% 
    
Smoking status 97 578 291  
    Current 97 196 840 34% 
    Other 97 381 451 66% 
    
Alcohol status 74 411 109  
    Current 67 254 896 62% 
    Other 72 156 213 38% 
 
*2 studies provided data on history of diabetes but were not included in the analyses of diabetes because 
none of the participants (MRFIT) and all of the participants with history of diabetes information (HBS) had 
diabetes. A further 93 093 participants had information on fasting glucose concentration at baseline, but no 
information on self-reported diabetes status. 
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eTable 4 Summary of vascular outcomes recorded.   
 
Study No. of 
parti-   
cipants 
Median follow-up 








All      
CHD 
All      









































Cohort studies                    
ARIC 14590 14.0 (5.0 to 15.7) 1642 427 876 200 797 676 121 563 454 2 452 56 16 16 0 110 1501 
ATENA 4752 6.7 (5.2 to 8.1) 30 9 18 1 18 17 1 4 1 0 1 2 0 0 0 6 40 
ATTICA 1601 5.0 (5.0 to 5.0) 30 30 0 0 0 0 0 0 0 0 0 0 0 0 0 0 50 
BHS 6221 25.0 (7.1 to 33.2) 957 957 537 537 361 0 361 223 22 22 0 21 147 147 0 120 2045 
BRHS 6810 24.5 (4.7 to 25.4) 1858 776 1215 541 1037 674 363 516 7 7 0 13 475 67 408 85 1960 
BRUN 817 15.3 (3.9 to 15.5) 101 56 54 31 42 23 19 40 24 9 15 15 0 0 0 7 180 
BUPA 20884 23.7 (11.3 to 26.7) 1505 1505 1012 1012 612 0 612 254 31 31 0 37 145 145 0 164 3543 
BWHHS 3030 7.3 (3.1 to 8.4) 220 34 99 14 85 85 0 102 0 0 0 1 101 0 101 11 258 
CAPS 2161 13.0 (4.0 to 13.0) 295 155 254 114 214 140 74 19 3 3 0 4 9 9 0 15 348 
CASTEL 2534 11.2 (2.3 to 14.0) 533 533 97 97 97 0 97 109 0 0 0 0 109 109 0 327 1143 
CHARL 1945 23.8 (3.5 to 40.0) 921 575 509 293 356 216 140 251 29 29 0 35 173 43 130 87 1192 
CHS1 3872 12.1 (2.0 to 12.9) 1115 271 593 213 593 380 213 466 367 0 367 62 37 2 35 0 1072 
CHS2 473 9.1 (1.5 to 9.5) 109 27 54 21 54 33 21 49 40 0 40 5 4 0 4 0 92 
COPEN 8414 13.1 (2.4 to 14.9) 1467 396 544 51 493 493 0 628 387 3 384 74 136 23 113 159 1814 
DISCO 1932 5.5 (5.5 to 9.5) 12 12 9 9 5 0 5 3 1 1 0 1 1 1 0 0 29 
DRECE 2860 16.4 (15.5 to 16.6) 31 31 16 16 8 0 8 6 0 0 0 1 4 4 0 5 140 
DUBBO 2061 14.1 (1.8 to 14.9) 541 135 284 63 221 221 0 191 76 0 76 19 87 0 87 43 488 
EMOFRI 360 6.8 (6.5 to 7.2) 8 4 2 0 2 2 0 3 2 0 2 1 0 0 0 3 9 
EPESEBOS 1033 10.4 (6.4 to 10.9) 190 67 81 20 73 61 12 62 48 0 48 9 3 0 3 41 149 
EPESEIOW 1588 10.8 (6.8 to 11.1) 287 122 101 38 82 63 19 117 47 1 46 8 58 12 46 50 266 
EPESENCA 1348 10.4 (6.5 to 10.9) 241 79 100 32 82 68 14 100 61 1 60 8 30 4 26 35 196 
EPESENHA 814 10.5 (6.3 to 10.8) 179 86 55 7 52 48 4 47 32 0 32 3 12 2 10 60 146 
ESTHER 8042 5.0 (2.0 to 5.9) 211 22 78 11 76 67 9 129 3 3 0 1 124 2 122 2 100 
FINE_FIN 279 6.8 (0.9 to 10.0) 112 63 71 38 49 33 16 29 8 8 0 1 16 0 16 8 150 
FINE_IT 475 9.6 (1.8 to 21.4) 218 150 68 50 48 18 30 106 4 4 0 5 86 36 50 32 343 
FINRISK92 5263 11.8 (7.1 to 11.9) 295 60 150 31 134 119 15 123 83 0 83 36 0 0 0 15 244 
FINRISK97 6328 6.8 (6.0 to 6.9) 220 58 107 33 93 74 19 93 73 0 73 19 0 0 0 15 208 
FRAMOFF 2854 12.0 (4.7 to 14.4) 125 5 83 4 79 79 0 41 36 0 36 5 0 0 0 0 111 
GOH 2772 35.0 (14.4 to 36.0) 268 268 121 121 75 0 75 60 2 2 0 5 27 27 0 58 1025 
GOTO13 766 23.4 (5.0 to 30.5) 373 43 216 2 216 214 2 117 0 0 0 1 116 0 116 32 253 
GOTO33 733 12.8 (5.8 to 13.1) 44 22 27 13 23 14 9 8 0 0 0 0 8 0 8 4 81 
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cipants 
Median follow-up 
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GOTO43 773 10.0 (7.9 to 10.7) 42 4 28 1 28 27 1 12 9 1 8 1 1 0 1 1 25 
GOTOW 1455 32.2 (8.9 to 32.7) 369 131 148 54 148 94 54 179 0 0 0 0 179 35 144 0 408 
GREPCO 815 7.9 (7.7 to 8.9) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 5 
GRIPS 5786 9.8 (4.8 to 10.0) 449 47 299 0 299 299 0 103 0 0 0 0 103 0 103 43 225 
HBS 1142 20.5 (6.0 to 20.5) 113 113 75 75 0 0 0 24 0 0 0 0 24 24 0 0 359 
HELSINAG 527 8.3 (1.7 to 11.0) 135 135 56 56 39 0 39 53 28 28 0 3 4 4 0 17 310 
HISAYAMA 2576 14.0 (3.2 to 14.0) 356 76 77 10 70 67 3 220 148 1 147 49 0 0 0 27 387 
HONOL 2571 6.2 (1.4 to 7.6) 318 113 157 42 146 115 31 135 13 13 0 40 75 4 71 15 569 
HOORN 2230 8.8 (3.7 to 9.9) 172 70 73 13 72 60 12 53 3 3 0 4 46 4 42 44 213 
IKNS 8043 11.1 (5.1 to 18.6) 495 154 84 47 78 37 41 344 158 21 137 71 90 1 89 63 760 
ISRAEL 7838 23.3 (7.9 to 23.9) 1001 1001 733 733 0 0 0 268 0 0 0 0 268 268 0 0 2573 
KIHD 2068 20.1 (2.9 to 24.1) 588 61 406 17 399 389 10 153 111 8 103 35 3 0 3 12 348 
MALMO 32495 18.2 (7.9 to 22.6) 2418 1185 2047 814 1686 1233 453 144 36 36 0 49 17 17 0 94 3290 
MATISS83 2557 18.6 (6.4 to 19.5) 334 195 82 36 75 46 29 99 26 0 26 10 57 2 55 136 410 
MATISS87 2113 15.6 (7.0 to 16.2) 175 95 46 24 44 22 22 58 9 0 9 8 39 0 39 67 208 
MATISS93 1211 8.3 (6.8 to 9.3) 32 14 14 3 14 11 3 7 1 0 1 2 3 0 3 11 30 
MCVDRFP 23111 16.8 (13.6 to 18.9) 454 454 196 196 158 0 158 96 15 15 0 31 32 32 0 86 1770 
MESA 6760 4.8 (2.5 to 5.2) 172 21 83 14 69 69 0 83 67 0 67 13 2 1 1 0 143 
MICOL 23196 5.9 (4.7 to 7.1) 168 168 120 120 68 0 68 36 7 7 0 3 22 22 0 5 579 
MOGERAUG1 874 12.9 (3.6 to 13.4) 108 61 79 32 73 47 26 5 0 0 0 2 2 2 0 19 126 
MOGERAUG2 4025 7.9 (2.3 to 8.4) 130 67 105 42 97 63 34 7 1 1 0 1 3 3 0 14 203 
MOGERAUG3 3398 3.0 (1.8 to 3.6) 38 27 19 8 17 11 6 5 2 2 0 1 2 2 0 9 59 
MONFRI86 1138 16.7 (6.2 to 16.9) 84 49 24 6 24 18 6 17 8 0 8 3 5 0 5 42 133 
MONFRI89 1105 13.6 (6.7 to 13.7) 63 35 19 4 19 15 4 14 6 0 6 4 4 1 3 28 79 
MONFRI94 1296 8.5 (7.0 to 8.8) 40 13 11 0 11 11 0 17 6 0 6 7 2 0 2 11 40 
MORGEN 17739 10.8 (8.5 to 13.1) 150 150 77 77 61 0 61 25 4 4 0 10 4 4 0 24 590 
MOSWEGOT 4157 12.9 (7.6 to 18.6) 280 67 143 39 133 104 29 117 66 3 63 17 15 1 14 12 235 
MRCOLD 10521 8.5 (1.1 to 11.7) 2766 2766 0 0 0 0 0 0 0 0 0 0 0 0 0 0 6556 
NCS1 24238 16.1 (14.4 to 16.7) 553 553 378 378 287 0 287 67 9 9 0 17 12 12 0 84 1448 
NCS2 13106 17.3 (15.5 to 17.8) 282 282 195 195 154 0 154 27 2 2 0 6 6 6 0 40 815 
NCS3 10179 18.2 (12.1 to 18.8) 474 474 292 292 217 0 217 88 8 8 0 25 24 24 0 73 1011 
NFR 3133 10.2 (6.1 to 11.2) 127 127 93 93 63 0 63 27 2 2 0 9 11 11 0 5 340 
NHANESI 11621 18.4 (4.7 to 21.0) 1939 1211 1034 655 740 379 361 547 152 36 116 55 290 100 190 189 2747 
NHANESIII 12566 8.8 (3.4 to 11.8) 883 883 487 487 185 0 185 176 0 0 0 0 176 176 0 111 2086 
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NPHSII 2968 8.3 (3.4 to 10.4) 298 57 195 20 192 175 17 73 39 0 39 7 20 3 17 28 203 
NSHS 1944 9.6 (3.3 to 10.0) 109 56 37 37 23 0 23 58 1 1 0 1 55 2 53 14 56 
OSAKA 12307 10.2 (3.9 to 18.8) 268 108 43 16 37 27 10 148 60 11 49 27 45 0 45 72 637 
OSLO 17392 29.5 (10.9 to 30.5) 2638 2638 1617 1617 1101 0 1101 384 57 57 0 80 172 172 0 443 5944 
PARIS1 7079 22.9 (7.6 to 26.1) 603 603 341 341 0 0 0 100 0 0 0 0 100 100 0 0 2083 
PRHHP 6350 8.3 (5.1 to 12.0) 384 245 213 88 176 125 51 84 54 43 11 20 5 5 0 64 597 
PRIME 9582 5.2 (5.0 to 7.3) 208 37 146 17 141 129 12 42 33 0 33 6 3 0 3 17 185 
PROCAM 20218 9.9 (3.9 to 18.9) 742 302 486 119 428 367 61 106 77 9 68 22 7 7 0 136 1000 
QUEBEC 1307 5.3 (3.5 to 5.6) 55 13 35 2 35 33 2 9 0 0 0 0 9 0 9 7 51 
RANCHO 1806 14.1 (2.0 to 18.1) 515 115 225 3 223 222 1 188 0 0 0 1 178 0 178 41 498 
REYK 16840 24.7 (6.3 to 37.1) 4559 2526 3263 1230 2900 2033 867 769 183 183 0 162 244 244 0 344 6717 
ROTT 4823 12.0 (3.0 to 14.2) 670 455 250 35 245 215 30 146 39 39 0 23 64 64 0 165 1431 
SHHEC 10966 10.0 (6.9 to 10.0) 520 127 364 98 334 266 68 132 37 0 37 12 63 0 63 13 529 
SHS 4131 12.4 (2.0 to 14.3) 784 310 449 147 370 302 68 216 8 8 0 10 192 20 172 61 1157 
SPEED 2126 16.7 (3.3 to 18.2) 354 195 253 155 232 98 134 77 66 5 61 2 5 5 0 17 478 
TARFS 3535 15.6 (4.9 to 18.0) 348 286 243 189 79 54 25 65 1 1 0 0 64 56 8 28 532 
TROMSØ 22568 18.8 (5.1 to 19.3) 2138 344 1143 154 1095 989 106 829 610 1 609 101 64 16 48 121 1422 
ULSAM 2280 27.9 (6.5 to 35.9) 995 251 592 146 515 446 69 316 195 2 193 56 41 3 38 51 855 
VHMPP 66395 9.9 (1.3 to 13.7) 1191 1191 647 647 289 0 289 239 26 26 0 40 133 133 0 139 2568 
VITA 9031 3.3 (1.7 to 5.3) 66 21 38 8 37 30 7 19 15 0 15 2 1 1 0 7 87 
WHITEI 4013 8.2 (2.0 to 8.4) 471 471 217 217 96 0 96 140 20 20 0 14 73 73 0 85 1234 
WHITEII 10191 12.4 (4.8 to 14.1) 346 93 315 62 292 253 39 10 2 2 0 2 4 4 0 10 328 
WHS 28022 10.2 (8.4 to 10.8) 622 96 249 10 243 239 4 291 244 0 244 26 2 0 2 53 642 
ZARAGOZA 3662 5.1 (4.0 to 5.1) 127 37 59 21 59 38 21 68 16 16 0 0 52 0 52 0 39 
ZUTE 390 8.6 (1.1 to 10.1) 124 56 57 20 51 37 14 39 1 1 0 1 34 3 31 25 160 
Case-control studies                   
USPHS 934 - 0 0 244 22 244 221 22 0 153 5 147 0 0 0 0 0 0 
EPICNOR 1422 7.1 (2.2 to 9.3) 0 0 480 223 261 257 4 0 0 0 0 0 0 0 0 0 0 
FIA 2624 4.0 (0.5 to 9.3) 0 0 600 135 600 465 135 0 0 0 0 0 0 0 0 0 0 
FLETCHER 477 5.5 (1.8 to 6.4) 0 0 144 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
HPFS 736 6.0 (1.2 to 6.0) 0 0 218 32 197 186 11 0 0 0 0 0 0 0 0 0 0 
NHS 717 8.0 (1.4 to 8.8) 0 0 239 27 239 212 27 0 0 0 0 0 0 0 0 0 0 
Clinical trials                    
AFTCAPS 6577 5.1 (4.3 to 6.7) 190 26 146 4 146 142 4 23 22 0 22 0 1 1 0 12 57 
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ALLHAT 28146 4.4 (0.8 to 6.7) 1669 6 1126 5 1126 1121 5 543 0 0 0 0 543 1 542 0 11 
LEADER 941 4.2 (0.8 to 6.2) 182 95 99 63 79 36 43 67 52 7 45 3 12 6 6 11 184 
MRFIT 12840 6.9 (4.4 to 7.8) 896 256 767 184 711 583 128 80 5 5 0 4 61 4 57 26 484 
PROSPER 3253 3.2 (1.1 to 3.8) 395 88 266 65 201 201 0 115 0 0 0 0 115 9 106 0 243 
WOSCOPS 6214 4.8 (2.9 to 6.0) 452 80 371 71 300 300 0 72 0 0 0 0 72 0 72 0 185 
Studies with information on history of diabetes at baseline*                
TOTAL              
(97 studies) 592830 11.1 (3.2 to 25.9) 49086 25989 28856 12598 23247 16113 7133 12471 4649 681 3967 1466 5522 2044 3478 4438 72100 
                    
Studies with information on fasting glucose concentration               
TOTAL  
(54 studies) 288483 10.5 (2.1 to 26.1) 23862 11659 15120 6289 12371 8831 3540 5755 1924 399 1525 684 2670 987 1683 1921 31882 
                    
All studies                     
TOTAL  
(102 studies) 698782 10.8 (2.8 to 25.6) 52765 28964 31288 14406 24848 16737 8110 13113 4754 768 3985 1546 5879 2337 3542 4766 78853 
                                        
 
CVD indicates cardiovascular disease; CBVD cerebrovascular disease.  
*2 studies provided data on history of diabetes but were not included in the analyses of diabetes because none of the participants (MRFIT) and all of the participants with history of diabetes 
information (HBS) had diabetes.  3 studies (HELSINAG, VITA and VHMPP) did not provide data on history of diabetes.   
48 studies did not provide information on fasting glucose concentration.   
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eTable 5 Hazard ratios for coronary heart disease in people with diabetes compared with people without diabetes,  
progressively adjusted for baseline levels of several risk factors. 
 
(a) Adjusted for conventional risk factors. 
 Data from studies with complete information on sex, age, smoking, BMI, SBP, HDL-C, non-HDL-C and triglycerides 
With adjustment for ... HR (95% CI) 2 Q statistic (df) P for heterogeneity between studies I
2 (95% CI) 
 264 353 participants; 11 848 cases 
Age 2.06 (1.82, 2.34) 127 206 (60) <0.0001 71(62-78) 
Plus smoking 2.10 (1.85, 2.39) 134 202  (60) <0.0001 70(62-77) 
Plus BMI 2.00 (1.78, 2.25) 131 173  (60) <0.0001 65(55-74) 
Plus SBP 1.91 (1.70, 2.14) 119 163  (60) <0.0001 63(52-72) 
Plus non-HDL-C 1.93 (1.71, 2.16) 123 163 (60) <0.0001 63(51-72) 
Plus HDL-C 1.87 (1.67, 2.09) 119 149 (60) <0.0001 60(47-70) 
Plus log-triglycerides 1.87 (1.67, 2.09) 120 146 (60) <0.0001 59(45-69) 
 
 
(b) Adjusted for conventional risk factors and apolipoproteins. 
 Data from studies with complete information on sex, age, smoking, BMI, SBP, HDL-C, non-HDL-C and triglycerides 
With adjustment for ... HR (95% CI) 2 Q statistic (df) P for heterogeneity between studies I
2 (95% CI) 
 87 702 participants; 4998 
Age 2.42 (1.91, 3.08) 53 116 (21) <0.0001 82(74-88) 
Plus smoking 2.47 (1.95, 3.13) 57 111 (21) <0.0001 81(72-87) 
Plus BMI 2.29 (1.82, 2.87) 51 98 (21) <0.0001 78(68-86) 
Plus SBP 2.16 (1.73, 2.70) 46 92 (21) <0.0001 77(66-85) 
Plus Apo-B 2.19 (1.77, 2.71) 53 82 (21) <0.0001 74(61-83) 
Plus Apo-A1 2.11 (1.71, 2.61) 48 81 (21) <0.0001 74(60-83) 
Plus log-triglycerides 2.08 (1.69, 2.55) 48 75 (21) <0.0001 72(57-82) 
 
 
(c) Adjusted for conventional risk factors and waist-to-hip ratio (WHR). 
 Data from studies with complete information on sex, age, smoking, BMI, SBP, HDL-C, non-HDL-C and triglycerides 
With adjustment for ... HR (95% CI) 2 Q statistic (df) P for heterogeneity between studies I
2 (95% CI) 
 90 335 participants; 4552 cases 
Age 2.07 (1.76, 2.45) 75 59 (23) <0.0001 61(39-75) 
Plus smoking 2.12 (1.80, 2.51) 78 60 (23) <0.0001 61(40-75) 
Plus WHR 1.99 (1.72, 2.31) 85 45 (23) 0.0038 49(18-68) 
Plus SBP 1.87 (1.62, 2.17) 71 44 (23) 0.0049 48(16-68) 
Plus non-HDL-C 1.88 (1.62, 2.18) 68 46 (23) 0.0029 50(20-69) 
Plus HDL-C 1.81 (1.57, 2.09) 66 42 (23) 0.0088 45(12-66) 
Plus log-triglycerides 1.83 (1.59, 2.12) 68 41 (23) 0.0109 44(10-66) 
 
 
(d) Adjusted for other vascular risk factors. 
With adjustment for ... No. of participants No. of events HR (95% CI) Wald 2 
Conventional risk factors 129 569 6139 2.00 (1.69, 2.37) 64.7 
Plus fibrinogen 129 569 6139 1.95 (1.65, 2.29) 63.6 
Conventional risk factors 80 563 4631 1.93 (1.61, 2.32) 50.2 
Plus log-CRP 80 563 4631 1.90 (1.59, 2.28) 49.4 
Conventional risk factors 144 998 7541 1.81 (1.57, 2.09) 64.8 
Plus eGFR 144 998 7541 1.81 (1.57, 2.10) 64.4 
Conventional risk factors 96 524 5641 1.65 (1.45, 1.90) 53.1 
Plus fasting glucose 96 524 5641 1.54 (1.35, 1.75) 42.4 
 
Conventional risk factors included age, smoking status, BMI, systolic blood pressure, non-HDL-C, HDL-C and log 
triglycerides. Studies with fewer than 11 events for an outcome were excluded from the analysis of that outcome. All 
regression analyses were stratified, where appropriate, by sex and trial group. 
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eTable 6 Change in metrics of vascular disease risk prediction upon addition of history of diabetes or fasting 
glucose  concentration to a reference model containing conventional risk factors 
 
Covariate added to reference 
model 
Increment in C-index 
 (95% CI) 
Net reclassification  
improvement  (95% CI) 
Integrated discrimination 
improvement (95% CI) 
Diabetes 0.0081 (0.0065, 0.0098) 
P<0.0001 




IFG in people without diabetes 0.0000 (-0.0000, 0.0001) 
P=0.243 
-0.0050 (-0.0012, 0.0020) 
P=0.180 
0.00001 (0.000006, 0.000013) 
P<0.0001 
Fasting glucose‡ in people without 
diabetes 
0.0002 (-0.0002, 0.0007) 
P=0.256 
-0.0018 (-0.0080, 0.0044) 
P=0.571 




Vascular disease was defined as first-ever fatal or non-fatal coronary heart disease or cerebrovascular outcome. The reference model 
with conventional risk factors (stratified by sex) included age, smoking status, systolic blood pressure, total cholesterol and HDL 
cholesterol. People were classified as having diabetes based on self-report or fasting glucose ≥7 mmol/L. Impaired fasting glucose 
(IFG) was defined by ADA criteria (5.6-7 mmol/L) 
‡ To accommodate for a non-linear association, fasting glucose concentration was entered as a categorical variable (categories: <4, 4-
4.5, 4.5-5, 5-5.5, 5.5-6, 6-6.5 and 6.5-7 mmol/L) 
 
Assessments of the C-index were restricted to 112 913 participants (9973 cases) with information on both history of diabetes and 
fasting glucose concentration. Of these, 94 268 participants (7860 cases) did not have diabetes at baseline (and contributed to the 
analyses of fasting glucose). Assessments of net reclassification improvement and integrated discrimination improvement were 
restricted to 36 093 participants (3865 cases) with information on both history of diabetes and fasting glucose concentration and 
followed up for at least 10 years. Of these, 31 821 participants (2952 cases) did not have diabetes at baseline and contributed to the 






eTable 7 Hazard ratios for coronary heart disease and ischaemic stroke in people with diabetes at baseline 
compared with people without diabetes, progressively adjusted for usual levels of conventional risk 
factors 
 
 Data from studies with complete information on sex, age, smoking, BMI, SBP, HDL-C, non-HDL-C and triglycerides 
With adjustment for ... HR (95% CI) 2 Q statistic (df) P for heterogeneity between studies I
2 (95% CI) 
Coronary heart disease 264 353 participants; 11 848  
Age 2.06 (1.82, 2.34) 126.7 206 (60) <0.0001 71 (62-77) 
Plus smoking 2.06 (1.82, 2.34) 125.7 206 (60) <0.0001 71 (62-78) 
Plus BMI 2.01 (1.78, 2.27) 127.1 185 (60) <0.0001 68 (58-75) 
Plus SBP 1.87 (1.66, 2.09) 114.4 160 (60) <0.0001 62 (50-71) 
Plus non-HDL-C 1.93 (1.72, 2.17) 124.1 162 (60) <0.0001 63 (51-72) 
Plus HDL-C 1.84 (1.65, 2.05) 117.9 143 (60) <0.0001 58 (44-68) 
Plus log-triglycerides 1.83 (1.64, 2.04) 116.3 139 (60) <0.0001 57 (42-68) 
Ischaemic stroke 157 315 participants; 2858 cases 
Age 2.56 (2.15, 3.05) 112.4 47 (25) 0.0047 47 (16-66) 
Plus smoking 2.58 (2.16, 3.09) 108.5 49 (25) 0.0025 49 (20-68) 
Plus BMI 2.51 (2.12, 2.96) 116.8 43 (25) 0.0150 41 (7-63) 
Plus SBP 2.22 (1.90, 2.59) 101.1 37 (25) 0.0542 33 (0-58) 
Plus non-HDL-C 2.23 (1.91, 2.60) 102.1 37 (25) 0.0572 33 (0-58) 
Plus HDL-C 2.19 (1.89, 2.53) 108.6 34 (25) 0.1158 26 (0-54) 
Plus log-triglycerides 2.18 (1.89, 2.52) 113.8 32 (25) 0.1579 22 (0-52) 
 
Note: Studies with fewer than 11 events for an outcome were excluded from the analysis of that outcome. All regression analyses 




eTable 8 Population attributable fraction for vascular death associated with diabetes 
 
 
Prevalence of diabetes among cases Population attributable fraction (95% CI) 
11.5% (observed) 5.3% (4.6%, 5.9%) 
Hypothetical examples  
20% 10.8% (10%, 11.7%) 
40% 21.7% (19.9%, 23.4%) 
 
The observed diabetes prevalence among cases of 11.5% (10.0% - 12.9%) corresponds to diabetes prevalence 
in the general population of 7.0% (6.1% - 7.9%).  Regression analyses were stratified, where appropriate, by 
sex and trial group, and adjusted for age, smoking status, BMI and systolic blood pressure.  
Overall population attributable fractions (PAF) presented were calculated by random effects meta-analysis of 
study specific PAFs. Study specific PAFs were calculated using the formula: PAF = Pe * (RR-1) / RR, 




eTable 9 Population attributable fraction for vascular death associated with diabetes, after making 





Prevalence of diabetes among cases 
10% 20% 30% 
Baseline 5.0% (4.5%, 5.5%) 10.0% (9.0%, 10.9%) 15.0 % (13.5%, 16.4%) 
Incident rate of diabetes (% per year) 
0% 4.7% (4.2%, 5.2%) 9.4% (8.4%, 10.3%) 14.2% (12.7%, 15.5%) 
0.1% 4.8% (4.3%, 5.2%) 9.6% (8.6%, 10.5%) 14.3% (12.9%, 15.7%) 
0.3% 4.9% (4.4%, 5.3%) 9.8% (8.8%, 10.7%) 14.7% (13.2%, 16.0%) 
0.5% 5.0% (4.5%, 5.4%) 10.0% (9.1%, 10.9%) 15% (13.6%, 16.3%) 
1% 5.3% (4.8%, 5.7%) 10.5% (9.6%, 11.4%) 15.8% (14.4%, 17.0%) 
1.5% 5.5% (5.0%, 5.9%) 11.0% (10%, 11.8%) 16.5% (15%, 17.7%) 
 
 




































eAppendix 1. List of studies’ acronyms  
 
AFTCAPS, Air Force/Texas Coronary Atherosclerosis Prevention Study  
ALLHAT, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial  
ARIC, Atherosclerosis Risk in Communities Study 
ATENA, cohort of Progetto CUORE 
ATTICA, ATTICA Study 
BHS, Busselton Health Study  
BRHS, British Regional Heart Study  
BRUN, Bruneck Study  
BUPA, BUPA Study  
BWHHS, British Women's Heart and Health Study  
CaPS, Caerphilly Prospective Study  
CASTEL, Cardiovascular Study in the Elderly  
CHARL, Charleston Heart Study 
CHS-1, cohort of Cardiovascular Health Study (CHS) 
CHS-2, cohort of Cardiovascular Health Study (CHS) 
COPEN, Copenhagen City Heart Study  
CUORE, Progetto CUORE 
DISCO, District of Sezze Chronic Disease Control Programme, cohort of Risk Factors and Life Expectancy Pooling Project (RIFLE) 
DRECE, Diet and Risk of Cardiovascular Disease in Spain  
DUBBO, Dubbo Study of the Elderly  
EMOFRI, cohort of Progetto CUORE 
EPESEBOS, The Established Populations for the Epidemiologic Study of the Elderly Studies, Boston  
EPESEIOW, The Established Populations for the Epidemiologic Study of the Elderly Studies, Iowa  
EPESENCA, The Established Populations for the Epidemiologic Study of the Elderly Studies, North Carolina 
EPESENHA, The Established Populations for the Epidemiologic Study of the Elderly Studies, New Haven  
EPICNOR, EPIC Norfolk Study  
ESTHER, Epidemiologische Studie zu Chancen der Verhütung, Früherkennung und Therapie chronischer Erkrankungen in der 
älteren Bevölkerung  
FIA, First myocardial infarction in Northern Sweden 
FINE-FIN, Finland, Italy and Netherlands Elderly Study - Finland cohort 
FINE-IT, Finland, Italy and Netherlands Elderly Study – Italian cohort 
FINRISK-92, Finrisk Cohort 1992 
FINRISK-97, Finrisk Cohort 1997 
FLETCHER, Fletcher Challenge Blood Study 
FRAMOFF, Framingham Offspring Study 
GLOSTRUP, Glostrup Study 
GOH, The Glucose Intolerance, Obesity and Hypertension Study 
GOTO13, Göteborg 1913 Study  
GOTO33, Göteborg 1933 Study  
GOTO43, Göteborg 1943 Study  
GOTOW, Population Study of Women in Gothenburg, Sweden  
GREPCO, cohort of Risk Factors and Life Expectancy Pooling Project (RIFLE) 
GRIPS, Göttingen Risk Incidence and Prevalence Study  
HBS, Helsinki Businessmen Study 
HELSINAG, Helsinki Aging Study 
HISAYAMA, Hisayama Study 
HONOL, Honolulu Heart Program  
HOORN, Hoorn Study  
HPFS, Health Professionals Follow-up Study 
IKNS, Ikawa, Kyowa, and Noichi Study  
ISRAEL, Israeli Ischaemic Heart Disease Study 
KIHD, Kuopio Ischaemic Heart Disease Study  
LASA, Longitudinal Aging Study Amsterdam 
LEADER, Lower Extremity Arterial Disease Event Reduction Trial  
MALMO, Malmö Preventative Project 
MATISS-83, cohort of Progetto CUORE 
MATISS-87, cohort of Progetto CUORE 
MATISS-93, cohort of Progetto CUORE 
MCVDRFP, Monitoring of CVD Risk Factors Project 
MESA, Multi-ethnic Study of Atherosclerosis 
MICOL, cohort of Risk Factors and Life Expectancy Pooling Project (RIFLE) 
MOGERAUG1, MONICA/KORA Augsburg Surveys S1 
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MOGERAUG2, MONICA/KORA Augsburg Surveys S2 
MOGERAUG3, MONICA/KORA Augsburg Surveys S3 
MONFRI-86, cohort of Progetto CUORE 
MONFRI-89, cohort of Progetto CUORE 
MONFRI-94, cohort of Progetto CUORE 
MORGEN, Monitoring Project on Chronic Disease Risk Factors 
MOSWEGOT, MONICA Göteborg Study  
MRCOLD, MRC Study of Older People 
MRFIT, Multiple Risk Factor Intervention Trial 1  
NCS 1, 2 and 3, Norwegian Counties Studies 
NFR, cohort of Risk Factors and Life Expectancy Pooling Project (RIFLE) 
NHANES I, First National Health and Nutrition Examination Survey 
NHANES III, Third National Health and Nutrition Examination Survey 
NHS, Nurses' Health Study 
NORTH KARELIA, North Karelia Project 
NPHSII, Northwick Park Heart Study II  
NSHS, Nova Scotia Health Survey 
OSAKA, Osaka Study  
OSLO, Oslo Study 
PARIS1, Paris Prospective Study I 
PREVEND, Prevention of Renal and Vascular Endstage Disease Study 
PRHHP, Puerto Rico Heart Health Program 
PRIME, Prospective Epidemiological Study of Myocardial Infarction  
PROCAM, Prospective Cardiovascular Münster Study  
PROSPER, Prospective Study of Pravastatin in the Elderly at Risk  
QUEBEC, Quebec Cardiovascular Study  
RANCHO, Rancho Bernardo Study  
REYK, Reykjavik Study  
RIFLE, Risk Factors and Life Expectancy Pooling Project 
ROTT, The Rotterdam Study 
SHHEC, Scottish Heart Health Extended Cohort  
SHS, Strong Heart Study  
SPEED, Speedwell Study  
TARFS, Turkish Adult Risk Factor Study  
TROMSØ, Tromsø Study  
ULSAM, Uppsala Longitudinal Study of Adult Men  
USPHS, U.S. Physicians Health Study 
USPHS2, U.S Physicians Health Study 2 
VHMPP, Vorarlberg Health Monitoring and Promotion Programme 
VITA, Vicenza Thrombophilia and Athrosclerosis Project   
WHI-HaBPS, Women’s Health Initiative – Hormones and Biomarkers Preventing Stroke Study 
WHITE I, Whitehall I Study 
WHITE II, Whitehall II Study 
WHS, Womens Health Study  
WOSCOPS, West of Scotland Coronary Prevention Study  
ZARAGOZA, Zaragosa study  
ZUTE, Zutphen Elderly Study 
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